Phase I Study of Cisplatin Plus OSI-7904L in Patients With Solid Tumors
NCT ID: NCT00116896
Last Updated: 2009-01-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
25 participants
INTERVENTIONAL
2003-06-30
2004-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
7-hydroxystaurosporine and Cisplatin in Treating Patients With Advanced Malignant Solid Tumors
NCT00012194
Phase I Study of CBP501 and Cisplatin in Patients With Advanced Refractory Solid Tumors
NCT00551512
Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary Site
NCT00193609
Flavopiridol Plus Cisplatin or Carboplatin in Treating Patients With Advanced Solid Tumors
NCT00003690
UCN-01 and Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors
NCT00006464
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
OSI-7904L
Cisplatin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Advanced and/or metastatic solid tumor for which no effective therapy is available
* ECOG performance status 0-2
* Adequate bone marrow, hepatic and renal function
Exclusion Criteria
* Neurotoxicity \>= Grade 2
* Symptomatic brain metastases which are not stable
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
OSI Pharmaceuticals
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Vanderbilt Universtiy Medical Center
Nashville, Tennessee, United States
Institute for Drug DevelopmentCancer Therapy & Research Center
San Antonio, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OSI-904-102
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.